PCM
ALXN

Prelude Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Prelude Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-124,788
Closed -$22.9M – 2201
2021
Q2 		$22.9M Buy
124,788
+78,136
+167% +$13.4M 0.68% 14
2021
Q1 		$7.13M Buy
46,652
+36,752
+371% +$5.69M 0.18% 70
2020
Q4 		$1.55M Buy
9,900
+5,222
+112% +$671K 0.04% 364
2020
Q3 		$535K Sell
4,678
-6,496
-58% -$701K 0.03% 429
2020
Q2 		$1.25M Buy
11,174
+10,848
+3,328% +$1.15M 0.07% 262
2020
Q1 		$29K Sell
326
-2,247
-87% -$221K ﹤0.01% 895
2019
Q4 		$278K Buy
2,573
+1,864
+263% +$199K 0.01% 750
2019
Q3 		$69K Sell
709
-11,134
-94% -$1.26M ﹤0.01% 1070
2019
Q2 		$1.55M Buy
+11,843
New +$1.53M 0.08% 246
2019
Q1 		– Sell
-124
Closed -$15.4K – 2337
2018
Q4 		$12K Buy
+124
New +$14.7K ﹤0.01% 1350
2018
Q3 		– Sell
-3,894
Closed -$483K – 2161
2018
Q2 		$483K Buy
+3,894
New +$455K 0.03% 543
2018
Q1 		– Sell
-7,683
Closed -$918K – 1806
2017
Q4 		$919K Buy
+7,683
New +$936K 0.07% 274
2017
Q3 		– Sell
-12,470
Closed -$1.52M – 1990
2017
Q2 		$1.52M Buy
12,470
+9,312
+295% +$1.08M 0.14% 147
2017
Q1 		$383K Buy
3,158
+2,755
+684% +$355K 0.04% 372
2016
Q4 		$49K Buy
+403
New +$49.3K 0.01% 1052
2016
Q2 		– Sell
-775
Closed -$108K – 1811
2016
Q1 		$108K Sell
775
-4,482
-85% -$658K 0.02% 744
2015
Q4 		$1M Buy
5,257
+636
+14% +$111K 0.16% 157
2015
Q3 		$723K Buy
4,621
+186
+4% +$33.9K 0.11% 224
2015
Q2 		$802K Sell
4,435
-901
-17% -$155K 0.11% 211
2015
Q1 		$925K Buy
5,336
+3,441
+182% +$623K 0.13% 194
2014
Q4 		$351K Sell
1,895
-200
-10% -$37.1K 0.05% 426
2014
Q3 		$347K Buy
2,095
+328
+19% +$53.9K 0.05% 509
2014
Q2 		$276K Sell
1,767
-3,381
-66% -$534K 0.04% 609
2014
Q1 		$783K Buy
5,148
+1,176
+30% +$187K 0.1% 252
2013
Q4 		$528K Hold
3,972
– – 0.09% 337
2013
Q3 		$461K Sell
3,972
-6,000
-60% -$658K 0.07% 317
2013
Q2 		$920K Buy
+9,972
New +$961K 0.2% 117

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Prelude Capital Management's ALXN Position: Q3 2021 in Review

Prelude Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 124,788 shares — an estimated $22.9M sold.

Prelude Capital Management first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $22.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Prelude Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Prelude Capital Management sold 124,788 Alexion Pharmaceuticals shares in Q3 2021, an estimated $22.9M.
  • Prelude Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Prelude Capital Management's Alexion Pharmaceuticals position peaked at $22.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Prelude Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.